At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EPIX ESSA Pharma
Market Closed 04-17 16:00:00 EDT
1.79
+0.02
+1.13%
盘后1.79
+0.000.00%
16:49 EDT
| High1.81 | Low1.73 | Vol177.60K |
| Open1.77 | D1 Closing1.77 | Amplitude4.52% |
| Mkt Cap79.46M | Tradable Cap50.41M | Total Shares44.39M |
| T/O314.99K | T/O Rate0.63% | Tradable Shares28.16M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Soleus Capital Master Fund-Believe It Is in Shareholders’ Best Interest for ESSA Pharma to Wind Down Operations,Return Remaining Cash to Shareholders
THOMSON REUTERS · 04-15
Soleus Capital Master Fund, L.p. Reports 5.1 % Stake in ESSA Pharma Inc as of April 15 - SEC Filing
THOMSON REUTERS · 04-15
Bvf Partners L P Says Purchased ESSA Pharma Securities Based on Belief That Such Securities, When Purchased, Were "Undervalued"
THOMSON REUTERS · 04-09
Bvf Partners L P Reports 19.7% Stake in ESSA Pharma Inc as of April 9 - SEC Filing
THOMSON REUTERS · 04-09
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate
Simply Wall St. · 04-01
EPIX Lawsuit Alert! Class Action Lawsuit Against ESSA Pharma, Inc.
TIPRANKS · 03-20
Press Release: ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Dow Jones · 03-06
ESSA Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 02-11
ESSA Pharma Q1 2025 GAAP EPS $(0.19) Misses $(0.12) Estimate, Cash $120.6M
Benzinga · 02-11
ESSA Pharma: Fiscal Q1 Earnings Snapshot
Associated Press Finance · 02-11
ESSA Pharma Inc - Terminates Masofaniten Clinical Trials, Exploring Strategic Options
THOMSON REUTERS · 02-11
ESSA Pharma Inc - Strategic Options Include Merger, Take-Over, Asset Sale
THOMSON REUTERS · 02-11
ESSA Pharma Q1 Operating Expenses USD -9.685 Million
THOMSON REUTERS · 02-11
ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
CNW Group · 02-11
ESSA Pharma Inc expected to post a loss of 18 cents a share - Earnings Preview
Reuters · 02-07
ESSA Pharma Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky LLP Before March 25, 2025 to Discuss Your Rights – EPIX
TIPRANKS · 01-27
BUZZ-ESSA Bancorp jumps on $214 mln buyout deal with CNB Financial
Reuters · 01-10
3 Promising US Penny Stocks With Market Caps Under $80M
Simply Wall St. · 01-01
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?
Simply Wall St. · 2024-12-21
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?
ESSA Pharma Inc. Reports Strategic Shift Amid Losses
TIPRANKS · 2024-12-18
Introduction
Company Name.
ESSA Pharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App